Modern Pediatrics. Ukraine. (2022). 8(128): 12-20. doi 10.15574/SP.2022.128.12
Marushko T. V., Kurilina T. V., Kulchytska Ye.-E. B.
Shupyk National Healthcare University of Ukraine, Kyiv

For citation: Marushko TV, Kurilina TV, Kulchytska Ye-EB. (2022). Lipid profile peculiarities and matrix Gla protein concentration in Ukrainian pediatric patients with heterozygous familial hypercholesterolemia. Modern Pediatrics. Ukraine. 8(128): 12–20. doi 10.15574/SP.2022.128.12.
Article received: Sep 28, 2022. Accepted for publication: Dec 20, 2022.

Atherosclerotic changes in the vascular walls begin early in childhood, especially in association with familial hypercholesterolemia (FH). The process may be subclinical, which nevertheless requires therapeutic and preventive measures.
Purpose – to evaluate baseline lipid profiles, the thickness of carotid intima-media complexes, blood pressure indices and the association with concentration changes of dephosphorylated-uncarboxylated matrix Gla protein (dp-uc MGP) as a marker of subclinical arterial lesions in different age groups of pediatric patients with FH.
Materials and methods. Children with heterozygous FH (n=15), stratified by age and sex, were included in the study. The control group consisted of healthy peers (n=21). Blood samples were analyzed to determine levels of total (TC), low-density (LDL-C), very-low-density (VLDL-C), high-density (HDL-C), remnant (rC) and non-high-density (non-HDL-C) cholesterol, triglycerides (TG), apolipoproteins A1 (apoA1) and B (apoB), lipoprotein (a), and dp-uc MGP. The intima-media complex thickness of the common carotid artery and blood pressure were measured in all study subjects. The obtained data were processed using the accepted methods of medical statistics and SAS^® OnDemand for Academics.
Results. Lipid profile changes in pediatric patients with FH were characterized by high levels of LDL-C, non-HDL-C and lipoprotein (a) in the 5-9 years age group; in the 10-14 years age group – high levels of LDL-C, TG, rC, non-HDL-C and lipoprotein (a); in the 15-18 years age group – high levels of LDL-C, TG, non-HDL-C and lipoprotein (a). At the same time, the most marked dyslipidemia changes were evident in children aged 10-14 years in the FH group. apoA1 levels were significantly decreased in all FH children. Elevated levels of lipoprotein (a) (>30 mg/dL) in FH children were found in all age groups, suggesting that elevated lipoprotein (a) levels can be used as a factor for cardiovascular risk stratification. Dp-uc MGP levels were significantly elevated in all age groups of FH children compared to healthy peers.
Conclusions. A lipid profile examination is necessary to diagnose FH in children, along with family health history and cascade screening. As atherosclerotic changes at 5-18 years of age remain subclinical, and the instrumental tests available in routine medical practice are not sensitive enough to detect them, therefore, preventive or therapeutic measures cannot be initiated promptly. The evaluation of circulating matrix Gla protein in pediatric patients with FH can be used as a marker of vascular wall calcification, which may allow early preventive measures against microcalcification to be developed.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of the participating institution. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
Keywords: children, familial hypercholesterolemia, lipid profile, lipoprotein (a), dp-uc matrix Gla protein, intima-media complex thickness, apolipoprotein A1, apolipoprotein B.
REFERENCES

1. Balder J, Lansberg P, Hof M, Wiegman A, Hutten B, Kuivenhoven J. (2018, Sep). Pediatric lipid reference values in the general population: The Dutch lifelines cohort study. Journal of Clinical Lipidology. 12 (5): 1208-1216. https://doi.org/10.1016/j.jacl.2018.05.011; PMid:30007775

2. Béliard S, Carreau V, Carrié A, Giral P, Duchêne E, Farnier M et al. (2014). Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects. Atherosclerosis. 234 (1): 136-141. https://doi.org/10.1016/j.atherosclerosis.2014.02.021; PMid:24637413

3. Chiesa ST, Charakida M. (2019). High-Density Lipoprotein Function and Dysfunction in Health and Disease. Cardiovascular Drugs and Therapy. 33 (2): 207-219. https://doi.org/10.1007/s10557-018-06846-w; PMid:30675710 PMCid:PMC6509080

4. De Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS et al. (2019). Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. Circulation. 139 (13): e603-e634. https://doi.org/10.1161/CIR.0000000000000618

5. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL et al. (2011). ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European heart journal. 32 (14): 1769-1818. https://doi.org/10.1093/eurheartj/ehr158; PMid:21712404

6. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, & National Heart, Lung, and Blood Institute. (2011). Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 128 (5): S213-S256. https://doi.org/10.1542/peds.2009-2107C; PMid:22084329 PMCid:PMC4536582

7. Friedewald WT, Levy RI, Fredrickson DS. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 18 (6): 499-502. https://doi.org/10.1093/clinchem/18.6.499; PMid:4337382

8. Heidemann BE, Koopal C, Bots ML, Asselbergs FW, Westerink J, Visseren FL. (2021). The relation between VLDL-cholesterol and risk of cardiovascular events in patients with manifest cardiovascular disease. International Journal of Cardiology. 322: 251-257. https://doi.org/10.1016/j.ijcard.2020.08.030; PMid:32810544

9. Jaminon A, Dai L, Qureshi AR, Evenepoel P, Ripsweden J, Söderberg M, Witasp A, Olauson H, Schurgers LJ, Stenvinkel P. (2020). Matrix Gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease. Scientific reports. 10 (1): 6586. https://doi.org/10.1038/s41598-020-63013-8; PMid:32313061 PMCid:PMC7171129

10. Juonala M, Wu F, Sinaiko A, Woo JG, Urbina EM, Jacobs D et al. (2020). Non-HDL Cholesterol Levels in Childhood and Carotid Intima-Media Thickness in Adulthood. Pediatrics. 145: 4. https://doi.org/10.1542/peds.2019-2114; PMid:32209701 PMCid:PMC7111486

11. Kavey REW, Manlhiot C, Runeckles K, Collins T, Gidding SS, Demczko M et al. (2020, Nov). Effectiveness and Safety of Statin Therapy in Children: A Real-World Clinical Practice Experience. CJC Open. 2 (6): 473-482. https://doi.org/10.1016/j.cjco.2020.06.002; PMid:33305206 PMCid:PMC7710927

12. Kronenberg F, Mora S, Stroes E, Ference BA, Arsenault BJ, Berglund L et al. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European heart journal. 43 (39): 3925-3946. https://doi.org/10.1093/eurheartj/ehac361; PMid:36036785 PMCid:PMC9639807

13. Krysa JA, Vine DF, Beilin LJ, Burrows S, Huang RC, Mori TA, Proctor SD. (2020). ApoB48-remnant lipoproteins are associated with increased cardiometabolic risk in adolescents. Atherosclerosis. 302: 20-26. https://doi.org/10.1016/j.atherosclerosis.2020.04.021; PMid:32413793

14. Liabeuf S, Desjardins L, Diouf M, Temmar M, Renard C, Choukroun G, Massy ZA. (2015). The Addition of Vascular Calcification Scores to Traditional Risk Factors Improves Cardiovascular Risk Assessment in Patients with Chronic Kidney Disease. PloS one. 10 (7): e0131707. https://doi.org/10.1371/journal.pone.0131707; PMid:26181592 PMCid:PMC4504701

15. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. (2011). HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nature Reviews Cardiology. 8 (4): 222-232. https://doi.org/10.1038/nrcardio.2010.222; PMid:21304474

16. Nordestgaard BG, Varbo A. (2014). Triglycerides and cardiovascular disease. The Lancet. 384 (9943): 626-635. https://doi.org/10.1016/S0140-6736(14)61177-6; PMid:25131982

17. Pejic RN. (2014). Familial hypercholesterolemia. The Ochsner journal. 14 (4): 669-672.

18. Pirillo A, Catapano AL, Norata GD. (2019). Biological Consequences of Dysfunctional HDL. Current Medicinal Chemistry. 26 (9): 1644-1664. https://doi.org/10.2174/0929867325666180530110543; PMid:29848265

19. Ray KK, Ference BA, Séverin T, Blom D, Nicholls SJ, Shiba MH et al. (2022). World Heart Federation Cholesterol Roadmap 2022. Global Heart. 17 (1): 75. https://doi.org/10.5334/gh.1154; PMid:36382159 PMCid:PMC9562775

20. Rikhi R, Hammoud A, Ashburn N, Snavely AC, Michos ED, Chevli P, Tsai MY, Herrington D, Shapiro MD. (2022). Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2022.10.004; PMid:36253168

21. Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM, Shanahan CM, Vermeer C, Weissberg PL, Proudfoot D. (2007). Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. Journal of thrombosis and haemostasis. JTH. 5 (12): 2503-2511. https://doi.org/10.1111/j.1538-7836.2007.02758.x; PMid:17848178

22. Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G et al. (2008). The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrology Dialysis Transplantation. 23 (10): 3263-3271. https://doi.org/10.1093/ndt/gfn226; PMid:18463323

23. Tintut Y, Hsu JJ, Demer LL. (2018). Lipoproteins in Cardiovascular Calcification: Potential Targets and Challenges. Frontiers in Cardiovascular Medicine: 5. https://doi.org/10.3389/fcvm.2018.00172; PMid:30533416 PMCid:PMC6265366

24. Vermeer C, Drummen NEA, Knapen MHJ, Zandbergen FJ. (2015). Uncarboxylated Matrix Gla Protein as a Biomarker in Cardiovascular Disease: Applications for Research and for Routine Diagnostics. In: Patel, V., Preedy, V. (eds) Biomarkers in Cardiovascular Disease. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7741-5_14-1

25. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M et al. (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 42 (34): 3227-3337. https://doi.org/10.1093/eurheartj/ehab484; PMid:34458905

26. Zanoli L, Lentini P, Briet M, Castellino P, House AA, London GM et al. (2019). Arterial Stiffness in the Heart Disease of CKD. Journal of the American Society of Nephrology: JASN. 30 (6): 918-928. https://doi.org/10.1681/ASN.2019020117; PMid:31040188 PMCid:PMC6551785